Professor David Baldwin’s Lovefest With The Pharmaceutical Industry….


davidbaldwin

David… did you miss the part where it says on the doctors oath’ First do no harm?.

What did you think it said, ‘First do for Pharm(a)?’ …

https://www.theguardian.com/society/2003/mar/17/mentalhealth.politics

“…Dr Baldwin declared a personal interest in Lundbeck, manufacturers of the drug Citalopram. According to the minutes, however, he did not declare his connections with five other companies, including Seroxat manufacturers SmithKline Beecham, which is now GlaxoSmithKline…..”

The Guardian 2003..

https://player.fm/series/mad-in-america-science-psychiatry-and-social-justice/episode-47-conflicts-of-interest-questioned-in-review-of-prescribed-drug-dependence

Prof David Baldwin was instrumental in the promotion of Seroxat in the late 90’s. I hold him partly responsible for the damage that Seroxat did to me, and to many tens of thousands of others. He didn’t warn us of the serious side effects like akathisia, aggression, suicidal thoughts and withdrawals. He benefited (financially) while, I- and many others- suffered, being poisoned on a drug that should never have been licensed.

In the 1990’s Seroxat was a relatively new drug on the market, promoted and pushed heavily, by GSK and its legion of psychiatrists, academics, and doctors on its payroll at the time.

David Baldwin said of Seroxat, in 1998 (the year I was prescribed it -ironically).

“...Dr David Baldwin, senior lecturer in psychiatry at the University of Southampton, said it was one of the safest drugs ever made…

I find it remarkable how David Baldwin could state at the time that Seroxat was one of the safest drugs ever made, when little was known about how Seroxat would be received (in terms of millions of people being prescribed it). How could Baldwin know that Seroxat was one of the safest drugs ever made? He simply couldn’t know that, and to make a statement like that, is really quite audacious.

What Baldwin didn’t tell the public at the time (that he was making these outrageous statements to the media about Seroxat), was that he was also an utter whore to the pharmaceutical industry (and still is). He has more conflicts of interest than I’ve had hot dinners.

Of course, in the UK, there is virtually no transparency in relation to how much financial gain doctors like Baldwin get from promoting pharmaceutical products to the public whilst receiving payments from the drug manufacturers. Even when they do have to declare conflicts, it only has to be declared in relation to the topic at the time, and only in the last 3 years. Therefore, it can seem like doctors are a lot less in conflict that they usually are.

David Baldwin has blood on his hands from his promotion of Seroxat. How much money did GSK give him over the years? why don’t you tell the public, and the media, that David? and while your at it- why don’t you disclose the total sum of financial gain you’ve made from your faustian pact with the entire pharmaceutical industry (throughout your career) defending anti-depressants against criticism in the media?

What would Dr Baldwin say to all the families, parents, and friends of those who killed themselves from being prescribed a drug that is as harmful as Seroxat?

I hope Baldwin enjoys his piles of pharmaceutical money in this mortal sphere, you can’t spend it in hell David can you?

Because, for people like you, hell wouldn’t be hot enough.

Seroxat is not one of the safest drugs ever made David, it’s one of the most dangerous. You profited while people died on it. You promoted it, whilst also getting paid by the drug company. I almost lost my life on Seoxat, and it’s because of the greed and arrogance of psychiatrists like you that many people have been harmed by psychiatric medications. It doesn’t seem to matter to you that GSK are one of the most corrupt pharmaceutical companies on the planet, with a record of dodgy drugs, fraud, lies, and harm to patients.

You would take money from them despite knowing this.

Shameful.


For more on Dr Baldwin’s absolute prostitution of himself to the pharmaceutical industry see here-

https://holeousia.com/?s=David+Baldwin

For extensive links to Seroxat study 329, and its harms to kids, see here-

https://study329.org/

For other links to Seroxat horrors see here-

https://seroxatsecrets.wordpress.com/

For links to a complaint made about Baldwin see here –

http://cepuk.org/wp-content/uploads/2018/03/Complaint-to-RCPsych.pdf


Professor David Baldwin MA DM FRCPsych FHEA

David Baldwin is Professor of Psychiatry and Head of the Mental Health Group in the Clinical and Experimental Sciences Academic Unit of the Faculty of Medicine at the University of Southampton in the UK. He trained in medicine at Charing Cross Hospital Medical School, in psychiatry at St Mary’s Hospital Medical School and the Maudsley Hospital, and in medical humanities at Birkbeck College. He is an Honorary Professor in the University of Cape Town in South Africa and Visiting Professor at Suzhou University Guangji Hospital in China.He is current Chair of the Psychopharmacology Committee of the Royal College of Psychiatrists, Past President of Depression Alliance, a Medical Patron of Anxiety UK, Editor-in-Chief of Human Psychopharmacology, and author of over 260 full articles in peer-reviewed scientific journals.

Professor Baldwin aims to improve clinical outcomes in mood and anxiety disorders: by investigating the role of neurobiological and psychological factors in causing and maintaining illness; through improving trial design when evaluating efficacy and tolerability of treatment interventions; by assessing the effectiveness and acceptability of treatment interventions in wider clinical practice; through identifying more accurately those patient groups at particular risk of poor outcomes; and by offering a tertiary referral specialist clinical service to patients with chronic and treatment-resistant conditions.

Declaration of interests

Personal pecuniary interests: In the last three years (September 2014–August 2017), I have received honoraria for giving educational lectures in meetings organised by AstraZeneca, Janssen, H. Lundbeck A/S, Pierre Fabre and Pfizer. I have received financial support from the Ministry of Defence relating to my membership of its Research Ethics Committee. I have also received financial support from the Wiley publishing company relating to my editorship of the Human Psychopharmacology journal.

Personal family interest: My wife has received a personal honorarium for participating in an advisory board organised by H. Lundbeck A/S.

Non-personal pecuniary interest: In the last three years, my employer has received reimbursement for my time spent in attendance at advisory board meetings organised by Liva Nova and Mundipharma.

Personal non-percuniary interest: I am a Medical Patron of Anxiety UK and the University-nominated Governor on the Board of Southern Health NHS Foundation Trust (April 2017 onwards).


https://www.socialaudit.org.uk/43800073.htm

 

Dr Baldwin helped the manufacturers to launch Seroxat for social anxiety disorder, when he reportedly said, “Seroxat is one of the safest drugs ever made.” He co-authored two papers on this drug (1999 and 2000) one of which disclosed sponsorship by the manufacturers; the other didn’t but probably should have done. (Baldwin D, et al, (on behalf of the paroxetine study group) Paroxetine in social phobia/social anxiety disorder, Br J Psychiatry 1999 Aug, 175: 120-126. and Baldwin DS, Clinical experience with paroxetine in social anxiety disorder Int Clin Psychopharmacol 2000 July, 15 Suppl 1; S19-24)

Dr Baldwin was principal author of a Wyeth sponsored study, published in 2002. He was also identified as a member of the advisory board of Wyeth (Baldwin DS et al., Can we distinguish anxiety from depression? Psychopharmacol Bull, 2002 Summer, 36 Suppl 2, 158-165.)

Dr Baldwin has been identified also as a member of the Bristol Myers Squibb study group on CN-104-070 (nefazodone) (Baldwin DS et al, A randomised double blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment, J Psychopharmacol, 2001 Sept, 15(3), 161-165.)

In 1997, Dr Baldwin co-authored a paper on SSRIs with an employee of Pfizer (Lane R, Baldwin D., Selective serotonin reuptake Inhibitor-Induced serotonin syndrome, J Clin Psychopharmacol, 1997 June, 17(3), 208-221


https://www.medicinejournal.co.uk/article/S1357-3039(12)00194-6/abstract

David S Baldwin MBBS DM FRCPsych is Professor of Psychiatry and Head of Mental Health Group, University of Southampton, Faculty of Medicine, UK and Honorary Professor of Psychiatry, University of Cape Town, South Africa. Competing interests: DSB has acted as a consultant to and holds or has held research grants (on behalf of his employer) from a number of companies with an interest in anxiety and depressive disorders (Asahi, AstraZeneca, Cephalon, Eli Lilly, Grunenthal, GSK, Lundbeck, Organon, Pharmacia, Pierre Fabre, Pfizer, Roche, Servier, Sumitomo, and Wyeth)


 

 

 

 

 

 


 

https://www.independent.co.uk/life-style/health-and-families/health-news/antidepressant-seroxat-linked-to-suicide-attempts-among-adults-5347383.html

The antidepressant Seroxat has been linked to an increase in suicide attempts among adults. Researchers suggest that patients and doctors should be warned of the propensity to suicidal thoughts while on the drug.

Experts have already warned that Seroxat is not suitable for children and adolescents due to an increased risk of self harm.

In the new study of 916 adults on the drug, seven attempted to take their own life. Dr Ivar Aursnes and colleagues at the University of Oslo compared these findings with 550 patients taking a placebo, of whom one tried to commit suicide. Their conclusions are published in the journal BMC Medicine.

They say: “We conclude that the recommendation of restrictions in the use of paroxetine (Seroxat) in children and adolescents … should include usage in adults.”

Advertisements